According to the last available data from the World Health Organization*, in 2012 there were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer worldwide, making it one of the most impacting and challenging diseases of modern times. The pharmaceutical industry is actively targeting multiple aspects of oncology and there is an increasing need of compounds that can affect multiple processes at the same time.

We are developing four products for the treatment of several types of cancer: 4P-005, a NCE displaying high cytotoxic effects and immuno-modulating properties, 4P-009 a peptide for which we are currently establishing proof-of-concept and proof-of-mechanism, 4P-011, a peptide developed  to answer the urgent unmet need in the treatment of cancer resistance to chemotherapies, and 4P-012 a fixed dose combination product.

4p-pharma-cancer

*Source: http://globocan.iarc.fr